1. Home
  2. HURA vs PHLT Comparison

HURA vs PHLT Comparison

Compare HURA & PHLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • PHLT
  • Stock Information
  • Founded
  • HURA 2009
  • PHLT 1976
  • Country
  • HURA United States
  • PHLT United States
  • Employees
  • HURA N/A
  • PHLT N/A
  • Industry
  • HURA
  • PHLT Other Consumer Services
  • Sector
  • HURA
  • PHLT Consumer Discretionary
  • Exchange
  • HURA Nasdaq
  • PHLT Nasdaq
  • Market Cap
  • HURA 246.9M
  • PHLT 215.3M
  • IPO Year
  • HURA N/A
  • PHLT N/A
  • Fundamental
  • Price
  • HURA $4.76
  • PHLT $2.43
  • Analyst Decision
  • HURA Strong Buy
  • PHLT
  • Analyst Count
  • HURA 1
  • PHLT 0
  • Target Price
  • HURA $11.00
  • PHLT N/A
  • AVG Volume (30 Days)
  • HURA 262.4K
  • PHLT 168.5K
  • Earning Date
  • HURA 02-15-2025
  • PHLT 03-11-2025
  • Dividend Yield
  • HURA N/A
  • PHLT N/A
  • EPS Growth
  • HURA N/A
  • PHLT N/A
  • EPS
  • HURA N/A
  • PHLT N/A
  • Revenue
  • HURA N/A
  • PHLT $120,782,000.00
  • Revenue This Year
  • HURA N/A
  • PHLT $9.72
  • Revenue Next Year
  • HURA N/A
  • PHLT $9.90
  • P/E Ratio
  • HURA N/A
  • PHLT N/A
  • Revenue Growth
  • HURA N/A
  • PHLT 9.39
  • 52 Week Low
  • HURA $2.84
  • PHLT $2.29
  • 52 Week High
  • HURA $14.60
  • PHLT $4.35
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • PHLT N/A
  • Support Level
  • HURA N/A
  • PHLT N/A
  • Resistance Level
  • HURA N/A
  • PHLT N/A
  • Average True Range (ATR)
  • HURA 0.00
  • PHLT 0.00
  • MACD
  • HURA 0.00
  • PHLT 0.00
  • Stochastic Oscillator
  • HURA 0.00
  • PHLT 0.00

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About PHLT Performant Healthcare Inc. Common Stock

Performant Healthcare Inc delivers payment integrity solutions for its healthcare payer clients.

Share on Social Networks: